Skip to main content
N

NEURIZON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · NUZ ISIN · AU0000357261 LEI · 529900O3S715CU3F0342 ASX Professional, scientific and technical activities
Open in API
Filings indexed 119 across all filing types
Latest filing 2026-04-20 Share Issue/Capital Cha…
Country AU Australia
Listing ASX NUZ

About NEURIZON THERAPEUTICS LIMITED

https://www.neurizon.com/

Neurizon Therapeutics Limited is a clinical-stage company dedicated to the development of novel treatments for neurodegenerative diseases. The company's lead therapeutic candidate is monepantel (MPL), a small molecule compound that functions as a potent mTOR pathway modulator. By stimulating autophagy, monepantel aims to facilitate the clearance of misfolded protein aggregates associated with neuronal decay. The primary clinical focus is Amyotrophic Lateral Sclerosis (ALS) and Motor Neurone Disease (MND), where the candidate is being evaluated in advanced clinical trials. Neurizon's approach targets the fundamental biological drivers of neurodegeneration to slow disease progression and improve patient outcomes. The development program is supported by clinical data demonstrating the drug's safety, tolerability, and potential to impact biomarkers of neurodegeneration.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - NUZ 6 pages 18.4KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX Appendix 2A “Application for quotation of securities,” detailing the number and type of new ordinary shares to be quoted following a placement. It is clearly an announcement of a new share issue and related capital change under ASX Listing Rules, rather than an annual or interim report, earnings release, or proxy statement. This fits the definition of a Share Issue/Capital Change (SHA).
2026-04-20 English
Section 708A Cleansing Statement 2 pages 318.1KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX announcement under section 708A of the Corporations Act confirming the issuance of 33,212,500 new fully paid ordinary shares at $0.08 each, related to a placement and entitlement offer shortfall. It specifically details a new share issue and references lodging Appendix 2A for the share issue. This is a capital change announcement (new share issue), fitting the “Share Issue/Capital Change” category (SHA).
2026-04-20 English
Placement of Entitlement Offer Shortfall 2 pages 302.7KB
Capital/Financing Update Classification · 1% confidence The document is an ASX announcement describing the placement of an entitlement offer shortfall, detailing the amounts to be raised, share issue terms, settlement and allotment dates, and providing an update on the company’s capital raising. This is clearly a financing/capital structure update rather than an annual report, earnings release, management change, or legal notice. Therefore, it falls under the “Capital/Financing Update” category.
2026-04-15 English
Neurizon Investor Briefings Invitation 2 pages 297.5KB
Investor Presentation Classification · 1% confidence The document is an announcement inviting shareholders and prospective investors to in-person investor briefings where management will present corporate, clinical, and operational progress followed by Q&A. It is not a financial report itself, earnings release, or AGM material, but clearly relates to investor presentations. Therefore, it falls under the "Investor Presentation" category.
2026-04-15 English
Investor Presentation - April 2026 17 pages 1.7MB
Regulatory Filings
2026-04-09 English
NUZ-001 Data Shows Multi-Pathway Protein Clearance 3 pages 436.2KB
Regulatory Filings
2026-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.